Stake logo

AMAM

AMBRX BIOPHARMA INC-ADR

About AMAM

Ambrx Biopharma Inc. is a clinical-stage biologics company. The Company is focused on discovering and developing a class of engineered precision biologics (EPBs), using its expanded genetic code technology platform that allows to incorporate, in a site-specific manner, synthetic amino acids (SAAs) into proteins within living cells. Its product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation. Its SAA incorporation technology allows to develop a range of product candidate modalities, such as antibody-drug conjugates (ADCs), bispecific antibodies, PEGylated peptides, modified cytokines and immuno-stimulating antibody conjugates (ISACs). Its lead advanced internal product candidate is ARX788, an anti-HER2 ADC, being investigated in multiple clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction (GEJ) cancer and other solid tumors.

Buy US stocks in Australia starting with AMAM. Open an account and start investing today!

Market Capitalisation

$73.76M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

1

High today

$2.25

Low today

$1.93

Open price

$0.00

52-week high

$5.86

52-week low

$0.38


AMAM FAQs

One share of AMBRX BIOPHARMA INC-ADR is valued at $2.19.

The ticker symbol for AMBRX BIOPHARMA INC-ADR is AMAM.

To buy AMAM stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in AMAM

As of 25/01/2023 AMBRX BIOPHARMA INC-ADR has a market cap of $74M.

The AMBRX BIOPHARMA INC-ADR 52-week high stock price is $5.86.

The AMBRX BIOPHARMA INC-ADR 52-week low stock price is $0.38.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.